• Amgen highlighted real-world study results on thyroid eye disease, already presented at the 2026 ARVO meeting.
• Analysis covered more than 34,000 US patients, tracking disease course for up to eight years.
• Findings indicate thyroid eye disease often worsens beyond the early phase, challenging the traditional view of a predictable, self-limiting course.
• Progression appeared in many patients initially classified as mild, supporting longer-term monitoring and earlier intervention strategies in routine practice.
• Amgen’s observational research unit positioned the dataset as a platform to guide future evidence generation in rare-disease care.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Amgen Inc. published the original content used to generate this news brief on June 22, 2026, and is solely responsible for the information contained therein.